Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC

Fibrinolytic Therapy in Acute Stroke

Acute ischemic stroke is a major cause of morbidity and mortality in Europe, North America, and Asia. Its treatment has completely changed over the past decade with different interventional approaches, such as intravenous trials, intra-arterial trials, combined intravenous/intra-arterial trials, and newer devices to mechanically remove the clot from intracranial arteries. Intravenous thrombolys...

Fibrinolytic Therapy of Coronary Thrombosis.

Concurrent antiplatelet and fibrinolytic therapy.

In patients who have myocardial infarction with STsegment elevation, rupture of an atherosclerotic plaque leads to platelet adhesion, activation, and aggregation, with subsequent vessel occlusion due to thrombus formation. In these circumstances, the most effective pharmacologic reperfusion regimen is concurrent fibrinolytic therapy and platelet inhibition. The marked benefit of such a combinat...

Fibrinolytic Therapy in Meningitis and Ventriculitis.

Intrapleural Fibrinolytic Therapy in Loculated Effusions

Loculated pleural effusions are most commonly due to complicated parapneumonic effusions and empyema followed by tubercular pleural effusions and empyema, hemothorax and malignant effusions. Loculations develop due to delayed initiation and inappropriate use of antibiotics and, delayed initiation of pleural space drainage. The presence of loculations and thick viscous fluid leads to failed pleu...